- Previous Close
3.220 - Open
3.220 - Bid 3.160 x --
- Ask 3.190 x --
- Day's Range
3.170 - 3.220 - 52 Week Range
2.900 - 4.090 - Volume
49,500 - Avg. Volume
153,491 - Market Cap (intraday)
2.344B - Beta (5Y Monthly) -0.16
- PE Ratio (TTM)
8.34 - EPS (TTM)
0.380 - Earnings Date --
- Forward Dividend & Yield 0.60 (18.63%)
- Ex-Dividend Date Jun 14, 2024
- 1y Target Est
--
Golden Throat Holdings Group Company Limited, an investment holding company, manufactures and sells pharmaceutical, healthcare food, and other products in the People's Republic of China. The company offers Golden Throat Lozenges over-the-counter medicine to relieve symptoms of sore and dry throat, and hoarse voice caused by acute pharyngitis. It also provides Golden Throat Lozenge series products, which include Dule Lozenges; sugar-free Dule Lozenges; and other sugar free flavours, such as orange, fructus momordicae, chrysanthemum, American ginseng, and hawthorn. In addition, the company offers Yinxingye tablets to facilitate blood circulation, remove blood stasis, and dredge energy channels; Golden Throat intestinal series; and Golden Throat Compound Probiotic Lozenges. The company also exports its products to the United States, Canada, Japan, the European Union, Australia, Southeast Asia, the Middle East, Mexico, and Africa. Golden Throat Holdings Group Company Limited was founded in 1956 and is headquartered in Liuzhou, the People's Republic of China.
www.goldenthroat.com874
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 6896.HK
View MorePerformance Overview: 6896.HK
Trailing total returns as of 2/11/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6896.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6896.HK
View MoreValuation Measures
Market Cap
2.38B
Enterprise Value
1.82B
Trailing P/E
8.49
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.21
Price/Book (mrq)
1.74
Enterprise Value/Revenue
1.69
Enterprise Value/EBITDA
3.99
Financial Highlights
Profitability and Income Statement
Profit Margin
26.06%
Return on Assets (ttm)
10.80%
Return on Equity (ttm)
19.34%
Revenue (ttm)
1.01B
Net Income Avi to Common (ttm)
262.21M
Diluted EPS (ttm)
0.380
Balance Sheet and Cash Flow
Total Cash (mrq)
1.04B
Total Debt/Equity (mrq)
39.92%
Levered Free Cash Flow (ttm)
238.18M